Isoquercitrin inhibits the progression of liver cancer in vivo and in vitro via the MAPK signalling pathway Retraction in /10.3892/or.2023.8510

Huang,Guihong; Tang,Bo; Tang,Kun; Dong,Xiaomin; Deng,Jungang; Liao,Luqin; Liao,Zengzhen; Yang,Hua; He,Songqing

doi:10.3892/or.2014.3099

Isoquercitrin inhibits the progression of liver cancer in vivo and in vitro via the MAPK signalling pathway

Retraction in: /10.3892/or.2023.8510

Authors:
- Guihong Huang
- Bo Tang
- Kun Tang
- Xiaomin Dong
- Jungang Deng
- Luqin Liao
- Zengzhen Liao
- Hua Yang
- Songqing He
View Affiliations

Affiliations: Department of Pharmacy, Guilin Medical University, Affiliated Hospital, Guilin, Guangxi 541001, P.R. China, Department of Hepatobiliary Surgery, Guilin Medical University, Affiliated Hospital, Guilin, Guangxi 541001, P.R. China
Published online on: March 20, 2014 https://doi.org/10.3892/or.2014.3099
Pages: 2377-2384

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Liver cancer is a malignant tumour with high morbidity and fatality rates that is common worldwide. At present, the clinical approaches to treating primary liver cancer include partial hepatectomy, systemic or local chemotherapy, radiotherapy, radiofrequency ablative surgery and liver transplantation. However, all of these approaches have shortcomings, including poor prognosis and numerous side-effects. A large number of studies have proven that many effective ingredients in traditional Chinese medicine, particularly the flavonoid compounds extracted from plants, have achieved breakthroughs in terms of enhancing the effects and reducing the toxicity of chemotherapy and radiotherapy, preventing tumour metastasis and relapse after surgery, alleviating the clinical symptoms of advanced tumours, improving the quality of life of the patient with tumours and extending patient long‑term survival. The purpose of the present study was to investigate the impact of isoquercitrin, the flavonoid from Bidens bipinnata L. extract, on the progression of liver cancer and to achieve a deeper understanding of the biological characteristics of isoquercitrin's involvement in the progression of liver cancer. In the in vitro experiments, isoquercitrin was found to strongly inhibit the proliferation of human liver cancer cells, promote the apoptosis of human liver cancer cells, and block the cell cycle in the G1 phase. Isoquercitrin activated caspase-3, -8 and -9, inhibited the expression level of ERK and p38MAPK protein phosphorylation, and promoted the phosphorylation of JNK. Additionally, isoquercitrin reduced the expression level of PKC in human liver cancer cells. In the in vivo experiments, isoquercitrin was also found to significantly inhibit the growth of transplanted tumours in nude mice. The present study confirmed that isoquercitrin could inhibit the progression of human liver cancer in vivo and in vitro, and the molecular mechanism of isoquercitrin may be closely associated with the MAPK and PKC signalling pathways.

View Figures

View References

1	van Meer S, de Man RA, Siersema PD and van Erpecum KJ: Surveillance for hepatocellular carcinoma in chronic liver disease: evidence and controversies. World J Gastroenterol. 19:6744–6756. 2013.PubMed/NCBI
2	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
3	Liu Y, Chang CC, Marsh GM and Wu F: Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur J Cancer. 48:2125–2136. 2012. View Article : Google Scholar : PubMed/NCBI
4	Li M, Qiao C, Qin L, Zhang J and Ling C: Application of traditional Chinese medicine injection in treatment of primary liver cancer: a review. J Tradit Chin Med. 32:299–307. 2012. View Article : Google Scholar : PubMed/NCBI
5	Maluccio M and Covey A: Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
6	Belghiti J and Fuks D: Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer. 1:71–82. 2012. View Article : Google Scholar
7	Eguchi S, Kanematsu T, Arii S, Omata M, Kudo M, Sakamoto M, Takayasu K, Makuuchi M, Matsuyama Y and Monden M; Liver Cancer Study Group of Japan. Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Br J Surg. 98:552–557. 2011.PubMed/NCBI
8	Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, Xu Y and Zeng Y: A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 252:903–912. 2010. View Article : Google Scholar : PubMed/NCBI
9	Wang W, Shi J and Xie WF: Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int. 30:741–749. 2010. View Article : Google Scholar : PubMed/NCBI
10	Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Yu D, Meyer T, Patch DW and Burroughs AK: Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev. 32:594–606. 2006. View Article : Google Scholar : PubMed/NCBI
11	Roomi MW, Roomi NW, Kalinovsky T, Niedzwiecki A and Rath M: Micronutrient synergy in the fight against hepatocellular carcinoma. Cancers. 4:323–339. 2012. View Article : Google Scholar : PubMed/NCBI
12	Ghosh A, Ghosh D, Sarkar S, Mandal AK, Thakur Choudhury S and Das N: Anticarcinogenic activity of nanoencapsulated quercetin in combating diethylnitrosamine-induced hepatocarcinoma in rats. Eur J Cancer Prev. 21:32–41. 2012. View Article : Google Scholar : PubMed/NCBI
13	Khan MS, Halagowder D and Devaraj SN: Methylated chrysin induces co-ordinated attenuation of the canonical Wnt and NF-kB signaling pathway and upregulates apoptotic gene expression in the early hepatocarcinogenesis rat model. Chem Biol Interact. 193:12–21. 2011. View Article : Google Scholar
14	Liu H, Dong A, Gao C, Tan C, Xie Z, Zu X, Qu L and Jiang Y: New synthetic flavone derivatives induce apoptosis of hepatocarcinoma cells. Bioorg Med Chem. 18:6322–6328. 2010. View Article : Google Scholar : PubMed/NCBI
15	Ullmannova V and Popescu NC: Inhibition of cell proliferation, induction of apoptosis, reactivation of DLC1, and modulation of other gene expression by dietary flavone in breast cancer cell lines. Cancer Detect Prev. 31:110–118. 2007.PubMed/NCBI
16	Yang QH, Yang J, Liu GZ, Wang L, Zhu TC, Gao HL and Kou XG: Study on in vitro anti-tumor activity of Bidens bipinnata L. extract. Afr J Tradit Complement Altern Med. 10:543–549. 2013.PubMed/NCBI
17	Wu J, Wan Z, Yi J, Wu Y, Peng W and Wu J: Investigation of the extracts from Bidens pilosa Linn. var radiata Sch Bip for antioxidant activities and cytotoxicity against human tumor cells. J Nat Med. 67:17–26. 2013.
18	Kumari P, Misra K, Sisodia BS, Faridi U, Srivastava S, Luqman S, Darokar MP, Negi AS, Gupta MM, Singh SC and Kumar JK: A promising anticancer and antimalarial component from the leaves of Bidens pilosa. Planta Med. 75:59–61. 2009. View Article : Google Scholar : PubMed/NCBI
19	Kviecinski MR, Felipe KB, Schoenfelder T, de Lemos Wiese LP, Rossi MH, Gonçalez E, Felicio JD, Filho DW and Pedrosa RC: Study of the antitumor potential of Bidens pilosa (Asteraceae) used in Brazilian folk medicine. J Ethnopharmacol. 117:69–75. 2008.PubMed/NCBI
20	Ong PL, Weng BC, Lu FJ, Lin ML, Chang TT, Hung RP and Chen CH: The anticancer effect of protein-extract from Bidens alba in human colorectal carcinoma SW480 cells via the reactive oxidative species- and glutathione depletion-dependent apoptosis. Food Chem Toxicol. 46:1535–1547. 2008.PubMed/NCBI
21	Ma TT, Xie J, Zhang QL, Xu H, Li J and Chen FH: Analysis of fingerprint and bioactive components of Bidens biternata by HPLC. Zhong Yao Cai. 35:892–896. 2012.(In Chinese).
22	Zhong MM, Chen FH, Yuan LP, Wang XH and Wu FR: Study on the property of adsorption and separation of the macroporous resins for total flavonoids of Bidens bipinnata L. Zhong Yao Cai. 30:338–341. 2007.(In Chinese).
23	Zhong MM, Chen FH, Yuan LP, Wang XH, Wu FR, Yuan FL and Cheng WM: Protective effect of total flavonoids from Bidens bipinnata L. against carbon tetrachloride-induced liver injury in mice. J Pharm Pharmacol. 59:1017–1025. 2007.PubMed/NCBI
24	Yuan LP, Chen FH, Ling L, Bo H, Chen ZW, Li F, Zhong MM and Xia LJ: Protective effects of total flavonoids of Bidens bipinnata L. against carbon tetrachloride-induced liver fibrosis in rats. J Pharm Pharmacol. 60:1393–1402. 2008.PubMed/NCBI
25	Fabregat I, Roncero C and Fernández M: Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int. 27:155–162. 2007. View Article : Google Scholar : PubMed/NCBI
26	Koschny R, Brost S, Hinz U, Sykora J, Batke EM, Singer S, Breuhahn K, Stremmel W, Walczak H, Schemmer P, Schirmacher P and Ganten TM: Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma. BMC Cancer. 13:5322013. View Article : Google Scholar : PubMed/NCBI
27	Kumar S and Vaux DL: Apoptosis. A cinderella caspase takes center stage. Science. 297:1290–1291. 2002. View Article : Google Scholar : PubMed/NCBI
28	Dewson G and Kluck RM: Mechanisms by which Bak and Bax permeabilise mitochondria during apoptosis. J Cell Sci. 122:2801–2808. 2009. View Article : Google Scholar : PubMed/NCBI
29	Fombonne J, Bissey PA, Guix C, Sadoul R, Thibert C and Mehlen P: Patched dependence receptor triggers apoptosis through ubiquitination of caspase-9. Proc Natl Acad Sci USA. 109:10510–10515. 2012. View Article : Google Scholar : PubMed/NCBI
30	Rew DA and Wilson GD: Cell production rates in human tissues and tumours and their significance. Part II: clinical data. Eur J Surg Oncol. 26:405–417. 2000. View Article : Google Scholar : PubMed/NCBI
31	Kazi A and Dou QP: Cell cycle and drug sensitivity. Methods Mol Med. 111:33–42. 2005.
32	Fecher LA, Amaravadi RK and Flaherty KT: The MAPK pathway in melanoma. Curr Opin Oncol. 20:183–189. 2008. View Article : Google Scholar
33	Junttila MR, Li SP and Westermarck J: Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J. 22:954–965. 2008. View Article : Google Scholar : PubMed/NCBI
34	Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
35	Kohno M and Pouyssegur J: Targeting the ERK signaling pathway in cancer therapy. Ann Med. 38:200–211. 2006. View Article : Google Scholar : PubMed/NCBI
36	Das M, Garlick DS, Greiner DL and Davis RJ: The role of JNK in the development of hepatocellular carcinoma. Genes Dev. 25:634–645. 2011. View Article : Google Scholar : PubMed/NCBI
37	Dhanasekaran DN and Reddy EP: JNK signaling in apoptosis. Oncogene. 27:6245–6251. 2008. View Article : Google Scholar : PubMed/NCBI
38	Nateri AS, Spencer-Dene B and Behrens A: Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development. Nature. 437:281–285. 2005. View Article : Google Scholar : PubMed/NCBI
39	Marengo B, De Ciucis CG, Ricciarelli R, Furfaro AL, Colla R, Canepa E, Traverso N, Marinari UM, Pronzato MA and Domenicotti C: p38MAPK inhibition: a new combined approach to reduce neuroblastoma resistance under etoposide treatment. Cell Death Dis. 4:e5892013. View Article : Google Scholar : PubMed/NCBI
40	Guo K, Liu Y, Zhou H, Dai Z, Zhang J, Sun R, Chen J, Sun Q, Lu W, Kang X and Chen P: Involvement of protein kinase C β-extracellular signal-regulating kinase 1/2/p38 mitogen-activated protein kinase-heat shock protein 27 activation in hepatocellular carcinoma cell motility and invasion. Cancer Sci. 99:486–496. 2008.